{"id":1022240,"date":"2026-11-18T08:27:57","date_gmt":"2026-11-18T13:27:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/"},"modified":"2026-11-18T08:27:57","modified_gmt":"2026-11-18T13:27:57","slug":"telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/","title":{"rendered":"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <em>Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development<\/em>\n      <\/p>\n<p>\n        <em>Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027<\/em>\n      <\/p>\n<p>MIAMI, Nov.  18, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (\u201cTelomir\u201d or the \u201cCompany\u201d)<\/strong>, a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected <strong>Linical<\/strong>, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1\/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).<\/p>\n<p>Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first quarter of 2027.<\/p>\n<p>The engagement follows the U.S. Food and Drug Administration&#8217;s clearance of Telomir&#8217;s Investigational New Drug (IND) application and represents an important operational milestone as the Company advances toward clinical execution.<\/p>\n<p>\u201cFollowing FDA clearance of our IND, our priority has been to establish the clinical infrastructure necessary to advance Telomir-Zn into patients,\u201d said <strong>Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals<\/strong>. \u201cWe selected Linical for its extensive oncology experience, including breast cancer and early-phase clinical development. With our clinical trial agreements now executed, we are focused on advancing toward clinical initiation in the first quarter of 2027 and evaluating the potential of our novel oral epigenetic therapy in patients with triple-negative breast cancer.\u201d<\/p>\n<p>\u201cWe are pleased to partner with Telomir Pharmaceuticals as it prepares to evaluate Telomir-Zn in patients with triple-negative breast cancer,\u201d said <strong>Clareece West, President at Linical<\/strong>. \u201cOur CRO team brings extensive experience in oncology and early-phase clinical development to this partnership, and we look forward to helping Telomir advance their important clinical program.\u201d\u00a0<\/p>\n<p>\n        <strong>Linical&#8217;s Oncology and Breast Cancer Expertise<\/strong>\n      <\/p>\n<p>Linical is a global CRO with more than two decades of experience supporting oncology clinical development, including breast cancer and other solid tumors. Linical has completed numerous oncology clinical trials, with approximately half of its oncology experience concentrated in early-phase studies.<\/p>\n<p>Linical\u2019s oncology capabilities span Phase 1 through Phase 4 clinical development, encompassing clinical trial startup, investigator-site coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support.<\/p>\n<p>Linical&#8217;s established oncology infrastructure and experience in breast cancer research align with the operational needs of Telomir&#8217;s planned clinical program, supporting the company&#8217;s preparations for clinical evaluation of Telomir-Zn.<\/p>\n<p>\n        <strong>Advancing a Novel Oral Epigenetic Therapy for Triple-Negative Breast Cancer<\/strong>\n      <\/p>\n<p>Telomir-Zn is an investigational oral epigenetic therapy designed to regulate intracellular metal homeostasis and potentially reactivate silenced tumor suppressor genes involved in controlling cancer growth.<\/p>\n<p>The therapeutic approach is based on the role of intracellular metals, particularly iron, in regulating epigenetic processes. Certain cancers, including triple-negative breast cancer, exhibit increased dependence on iron-related biological pathways which support their uncontrolled growth. By modulating intracellular metal availability, Telomir-Zn inhibits several key iron-dependent epigenetic enzymes, thereby potentially restoring tumor suppressor gene functions.<\/p>\n<p>Preclinical research has demonstrated antitumor activity in TNBC models, supporting further investigation of Telomir-Zn in cancers with elevated iron dependency.<\/p>\n<p>In this upcoming FDA-cleared Phase 1\/2 clinical study, Telomir will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of Telomir-Zn as a monotherapy in patients with advanced or metastatic TNBC.<\/p>\n<p>The Company is advancing clinical trial preparations with Linical and continues to target clinical initiation in the first quarter of 2027.<\/p>\n<p>\n        <strong>About Linical<\/strong>\n      <\/p>\n<p>Linical is a global contract research organization providing comprehensive clinical development services to pharmaceutical and biotechnology companies. With operations across North America, Europe, and Asia-Pacific, Linical supports clinical trials across multiple therapeutic areas (including oncology, neurology, immunology, endocrinology, and rare disease) with a significant focus on early-phase clinical development.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cqNpjosp2aeI5eVr8LHqE6KxyNwyEVSqhGqVZIPmw8oyDA5kLHhjAGdOYEwhJbh3HRRi9VeJEk-XPXQGuwism8lp0GfjBrQxD0bIceIAU71D_7_yVssrRRKeqprhHc3dUBfNkXf3lgGMToZfRA7bGTE5HyhNUcgexOfbZnr6l6_WuBZ0cCvoGG98GDFxTkFtrRmff-knBfIMy8UShL_TAryz07e9ZTb_4eDk8gOG4qWWxsXW7J-NLjm9oN_T4BkZ3Ub1s_Jh6tWZivEyvpAy-siNDSNiACTNecsp_rl04QjIeXNXRgbvKPyt2d2br0qv9iy2JBwauoqjTPCntWggjdC4L9aNy6At6Ima_VKS_devD96GmTz_r9Nzca2CFx4gNJ_sotPJbMXPpkQd0FVYrG0HmgKmnXwTh-LdKItwmb0ywnyo-QpKcVWWYrF2z3ln\" rel=\"nofollow\" target=\"_blank\"><u>www.linical.com<\/u><\/a>.<\/p>\n<p>\n        <strong>About Telomir Pharmaceuticals<\/strong>\n      <\/p>\n<p>Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company\u2019s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1\/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iIZ4F276WN0ZCA10AVEHwJIXPf8yLhxBPW9ZDG3O6eu7rCYNTeCJ5feKN8MPLtdalwbGo6uym5Mr_pYtrUsZAMuCzx0WkhDbNhcKqrVq-zrPrL-QEGIw8e05b3VQUW__H_UdQF_tQ6n0pciIjXt-HY2-ut5KS_mgMvc0nWjIIo_pQo3n6oVl4IKMklXv0hjvjYy4hQTrEeYJk0peyuIxlULYnsaqEfFcWSmG9eHojFGJK3g76JWMx8mNaHw_W5C9OmfVI3LL086MddxsQm0PYGJcXy2zvpPeUUd97nfWOI8U1OcI_IojajMFVH5IveRAfzP1TWQY9p8gwIJ0ngRpZP7pbMCRkKXQl9Uj2CDStZi5bxHb8p09cQ1PLXRULF8HXS08iFbtReABfOX-y9dzQWsKZ8Vw1VGnydN4EofWJoaSc8wXQEVHvVv3PqxH8FGL\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/telomirpharma.com\/<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cforecast,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cguidance,\u201d \u201cpotential,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201ctarget,\u201d and other words of similar meaning, although not all forward-looking statements include these words.<\/p>\n<p>Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company\u2019s other product candidates. Forward-looking statements may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company\u2019s oncology development programs, the advancement of the Company\u2019s Phase 1\/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.<\/p>\n<p>These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management\u2019s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading \u201cRisk Factors\u201d contained in the Company\u2019s Annual Report on Form 10-K and the Company\u2019s other filings with the U.S. Securities and Exchange Commission (\u201cSEC\u201d).<\/p>\n<p>Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.<\/p>\n<p>We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the \u201cInvestors\u201d section of our website, for a discussion of these and other risks and uncertainties.<\/p>\n<p>\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p>Krystina Quintana<br \/>Email: info@telomirpharma.com<br \/>Phone: (786) 396-6723<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzU0YWI2MTMtMGU2ZC00MGYzLTg3OTAtN2Q2MjM1NTNjZWUwLTEyNzYxNTEtMjAyNi0xMS0xOC1lbg==\/tiny\/Telomir-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027 MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) &#8212; Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (\u201cTelomir\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected Linical, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1\/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC). Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1022240","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027 MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) &#8212; Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (\u201cTelomir\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected Linical, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1\/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC). Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, &hellip; Continue reading &quot;Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T13:27:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\\\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer\",\"datePublished\":\"2026-11-18T13:27:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/\"},\"wordCount\":1093,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/\",\"name\":\"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\\\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=\",\"datePublished\":\"2026-11-18T13:27:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\\\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer - Market Newsdesk","og_description":"Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027 MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) &#8212; Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (\u201cTelomir\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected Linical, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1\/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC). Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, &hellip; Continue reading \"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-18T13:27:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer","datePublished":"2026-11-18T13:27:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/"},"wordCount":1093,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/","name":"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=","datePublished":"2026-11-18T13:27:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MDAxMSM3OTcyNTU3IzIyNjQ2MDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of-telomir-zn-in-triple-negative-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1\/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022240"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}